Research Projects

By implementing and participating in different research projects, we support the research of ABCB5+ stem cells in order to be able to offer new fields of application and new chances to our clients.


Current Research Projects

TICEBA BlueMan Forschung

Limbal Stem Cell Deficiency

Tumor Diseases

Acute-on-Chronic Liver Failure

Acute Kidney Injury

Epdermolysis Bullosa

Peripheral Arterial Occlusive Disease

Chronic Venous Ulcers - autologous and allogeneic

Diabetic Foot Ulcers


Closed Researched Projects


TICEBA - Research - Clinical Phase
News
Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter